Diazepam Injection

Quick links to important sections

Diazepam Injection

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diazepam Injection

Property Description
Active ingredient Diazepam
Form Solution for Injection (Parenteral Preparation)
Pharmacological class Benzodiazepine / Central Nervous System (CNS) Depressant
General purpose Rapid stabilization and acute central relaxation
Origin Synthetic compound

What Type of Medicine is Diazepam Injection?

Diazepam Injection is a powerful prescription-only medicine containing the single active ingredient, Diazepam, a synthetic compound classified as a Central Nervous System (CNS) Depressant. Chemically, Diazepam belongs to the benzodiazepine class of drugs. This classification is rooted in the drug's core action: enhancing the effect of the brain's natural inhibitory neurotransmitter, GABA (gamma-aminobutyric acid).

Diazepam's primary mechanism involves promoting this calming action within the brain and spinal cord, effectively slowing down excessive neural signaling. This means the medicine works by making the brain's natural "brake" more powerful, promoting general relaxation. Diazepam is used for this stabilizing effect and has a long-established role in acute care settings.


Preparation and Purpose of the Injection Form

This medication is formulated as a specialized liquid, a solution for injection, which is a type of parenteral preparation administered directly into the body. As an INN (International Nonproprietary Name) product, Diazepam Injection is produced by numerous manufacturers globally, though the generic injection form is widely utilized across healthcare systems.

The purpose of this specialized formulation is directly linked to the need for speed. The injectable route provides a rapid onset of action, which is often essential for effective management in acute situations. This delivery method is chosen to ensure the medication starts working immediately, which is vital when a patient requires swift central nervous system control. This rapid action is fundamental to its general therapeutic purpose: providing immediate and profound central relaxation and stabilization during acute periods of neural overactivity.

Regulatory References

  1. U.S. National Library of Medicine
  2. [NIH, MedlinePlus]

What side effects are possible with Diazepam Injection?

Possible Side Effects and Safety Information

The official safety profile for Diazepam Injection is structured around its potent action as a Central Nervous System (CNS) depressant, classifying adverse reactions by frequency and organ system as documented in regulatory sources.


Frequency-Classified Adverse Reactions

Adverse effects are primarily CNS-related. Common reactions (occurring in 1% to 10% of users) typically include drowsiness, fatigue, ataxia (impaired coordination), and hypotension (low blood pressure). Local reactions at the administration site, such as pain or phlebitis, are also commonly reported. Uncommon effects include respiratory depression and amnesia, while Rare effects include severe hepatic dysfunction and paradoxical reactions (e.g., excitement, agitation).


Clinically Significant and Population-Specific Safety Notes

The label details serious adverse reactions, with the primary concern being the risk of respiratory depression and apnea, especially following rapid intravenous administration or when combined with other CNS depressants, such as opioids.

Regulatory documents also highlight population-specific safety considerations. Older adults may exhibit increased sensitivity to the CNS depressant effects, escalating the risk of oversedation and falls. The medicine is formally contraindicated in individuals with severe respiratory insufficiency, severe hepatic insufficiency, and Myasthenia Gravis. Physical dependence and withdrawal symptoms may develop with continued, prolonged exposure, a safety pattern explicitly noted by regulatory authorities.

Overdose and Emergency Response

Overdose with Diazepam Injection is characterized by a progression of Central Nervous System (CNS) depression, as documented in regulatory information. Initial manifestations may include drowsiness, confusion, and lethargy, advancing to impaired motor function such as ataxia, slurred speech, diminished reflexes, and hypotension. Severe, life-threatening outcomes officially documented in the labels include profound sedation, respiratory depression, coma, and death.

Official regulatory documents mandate that immediate medical attention be sought for any suspected overdose. Emergency medical care is required right away if symptoms include difficulty breathing or profound sedation, as these are indicators of severe toxicity.

Certain patient populations carry an officially documented increased risk. The elderly, the very ill, and those with limited pulmonary reserve are noted as having a higher susceptibility to apnea and cardiac arrest following intravenous administration. Additionally, the injection formulation carries a specific toxicity risk: massive doses may lead to Propylene Glycol Toxicity, potentially causing metabolic acidosis or cardiac arrhythmias.

Management is described as symptomatic and supportive, requiring continuous monitoring of vital signs and the maintenance of an adequate airway. The label notes that the benzodiazepine antagonist Flumazenil is an available treatment, though its use is cautioned due to the potential to precipitate acute withdrawal or seizures.

Therapeutic Uses of Diazepam Injection

What Diazepam Injection Treats: Main Uses and Benefits

Diazepam injection is applied for short-term, symptomatic assistance across several key therapeutic areas. It is considered relevant in contexts involving acute or unstable symptom patterns where temporary symptom stabilization is important. These therapeutic domains are commonly recognized for clinical application.

The injection is commonly used to help manage symptoms related to heightened physiological activity, such as acute agitation, and is applied in addressing symptoms associated with conditions like acute alcohol withdrawal, muscle spasms, and seizure episodes. The medication provides supportive relief when symptoms interfere with routine activities.

“It provides support that helps ease the overall symptom load, assisting with maintaining a sense of stability during acute or disruptive episodes.”


Key Therapeutic Domains

Easing Acute Symptomatic Discomfort

This injection is commonly used to help manage acute agitation and symptoms linked to organ-specific functional stress. It is also applied in addressing symptoms associated with acute alcohol withdrawal.

Quick Fact: Relevant for Acute Agitation Symptom Management

Supportive Management of Spasms and Convulsions

It is considered relevant in conditions involving increased neurological or muscular activity, and is relevant for easing symptoms associated with acute or recurrent seizure episodes. Furthermore, it is applied as an adjunct to address muscle spasms and spasticity.

Providing Relief in High-Tension Clinical Settings

The medication is helpful in situations requiring additional symptomatic assistance before or during certain medical or surgical procedures, easing symptoms related to physical discomfort and tension.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Diazepam Injection

The following rules for using Diazepam Injection are established in official government regulatory documents.

Populations for whom use is contraindicated:

  • Patients with a known hypersensitivity to diazepam or any of the product components.
  • Patients with Severe Respiratory Insufficiency or acute pulmonary insufficiency.
  • Patients with Sleep Apnoea Syndrome or Myasthenia Gravis.
  • Patients with Severe Hepatic Impairment or acute narrow-angle glaucoma.
  • Patients in shock, coma, or with acute alcoholic intoxication where vital signs are depressed.

Age-Related and Conditional Eligibility Rules:

Age Group / Condition Eligibility Status (as per official labeling)
Neonates (30 days of age and younger) Use Not Established; not recommended.
Older adults (Geriatric patients) Restricted; lower starting amounts are required.
Pregnancy and Lactation Not Recommended; use is discouraged, especially during the first and third trimesters.
Impaired Kidney or Moderate Liver Function Caution is required; may necessitate dose reduction.

The official eligibility profile is structured to exclude populations where the drug's metabolism is impaired or where its CNS depressant effects pose a high risk of respiratory or cardiac compromise.

What should I know about interactions with other medicines?

The official regulatory documentation for Diazepam Injection outlines critical interactions categorized by their effect on central nervous system (CNS) activity and drug metabolism.

Pharmacodynamic Interactions

Concomitant use of Diazepam Injection with other CNS Depressants, particularly Opioids, is highly restricted due to an additive CNS depressant effect. This combination carries a significant regulatory warning about the risk of profound sedation, respiratory depression, coma, and death. Similarly, the regulatory labels mandate that the use of Alcohol must be avoided, as it enhances sedative effects and increases the risk of respiratory complications. Other substances with CNS depressant properties, such as barbiturates and certain anticonvulsants, may also increase depression and the potential for adverse cardiorespiratory outcomes.

Pharmacokinetic Interactions

Interactions that alter the drug's clearance occur via enzyme pathways. Inhibitors of the CYP3A4 and CYP2C19 enzymes, including medicines like Cimetidine and certain antifungals, reduce the metabolic clearance of diazepam. This reduction can lead to increased plasma exposure and potentiated action. Conversely, strong enzyme inducers like Rifampicin substantially accelerate diazepam clearance, resulting in decreased plasma concentrations and a potentially reduced effect. Co-administration with Rifampicin should be avoided.

Population-Specific Notes

Regulatory cautions state that the risks associated with depressant interactions are amplified in the elderly and very ill patients, necessitating extreme care. Furthermore, impaired hepatic function may prolong the elimination half-life of diazepam, affecting overall drug exposure.

Mechanism of Action

Allosteric Enhancement of GABA A Receptor Activity

Diazepam functions as a positive allosteric modulator that binds to the benzodiazepine site on the gamma-aminobutyric acid type A ( GABA A) receptor, a ligand-gated chloride ion channel. This interaction potentiates the effect of the body's natural inhibitory neurotransmitter, GABA, leading to a greater frequency of channel opening. The resulting rapid influx of negatively charged chloride ions ( Cl^-) rapidly hyperpolarizes neurons across the central nervous system (CNS), which results in widespread CNS depression.


Targeted Reduction of CNS Excitability

The enhanced GABA signaling drastically reduces the ability of neurons in the cortex and associated areas to fire rapidly. This limits the capacity of neurons to sustain rapid, synchronized firing, resulting in anticonvulsant activity, as well as the generalized physiological consequences of sedation and reduced responsiveness within the limbic system.


Modulation of Spinal Cord Motor Control

This mechanism's influence extends to the motor system via the spinal cord's inhibitory interneurons within the polysynaptic reflex pathways. By limiting the excitatory drive to motor neurons at this central level, the mechanism produces the resultant physiological effect of decreased muscle tone.

Dosage and Administration Information

How to use Diazepam Injection

Diazepam Injection is a parenteral preparation indicated for administration via the Intravenous (IV) or Intramuscular (IM) route. The IV route is generally utilized for conditions requiring the most immediate effect, such as the acute management of severe, uncontrolled episodes. The IM route is approved but absorption may be slow and erratic.

Official Administration Guidelines

Parameter Description
Standard Adult Dosing Range Typically 2 mg to 10 mg IV or IM for initial symptom relief, repeatable in 3 to 4 hours if necessary.
Acute Seizure Dosing 5 mg to 10 mg IV, which may be repeated at 10- to 15-minute intervals, up to a total cumulative dose of 30 mg.
IV Injection Rate The solution must be administered slowly, taking at least one minute for each 5 mg delivered, except in specific emergency protocols.
Preparation Constraints The injection must not be mixed or diluted with other drugs or solutions in the syringe or infusion flask.
Population Adjustment Older Adults and Debilitated Patients require lower doses to be used, often 2 mg to 5 mg. Pediatric dosing is weight-based and subject to specific rate-of-administration constraints.

Use Pattern

Official instructions confirm the drug is intended only for short-term, intermittent use for acute symptom management and is not indicated as a therapy for continuous, long-term maintenance. Facilities capable of providing respiratory assistance are required to be readily available during intravenous use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diazepam Injection


Evidence for Use in Acute Seizure Episodes (Status Epilepticus)

Research for the injection was studied in the context of severe, prolonged seizure events. Short-term Randomized Controlled Trials (RCTs) were a primary study design, with research examined in both adult and pediatric patients. The main outcomes monitored by these studies included measures of the time to seizure cessation and the rate of seizure recurrence following the initial intervention. Clinical trial reports documented the time measurements for seizure cessation. The evidence is concentrated on the immediate effects, and there is limited long-term follow-up data available.


Evidence for Use in Acute Alcohol Withdrawal

The injection was studied in conditions related to acute alcohol withdrawal syndrome. Studies, including Randomized Controlled Trials (RCTs), examined administration approaches in adults presenting with moderate to severe withdrawal symptoms. Researchers monitored outcomes using standardized clinical rating scales and observed patterns related to preventing severe complications. Findings are confined to the acute phase of symptom management, and patient heterogeneity means consistent subgroup findings are uncertain.


Research in Spasms and Acute Agitation

Research was evaluated for its use in acute skeletal muscle spasms, primarily through older Clinical Trials and Observational Studies, examining outcomes related to spasm frequency and physical discomfort. Separately, RCTs examined the injection's use for addressing acute agitation and for the examination of tension relief during medical procedures, monitoring the time until a state of calmness was observed. The evidence in both areas is strongly focused on the immediate, transient nature of the required pattern.


Long-Term Studies and Research Gaps

Follow-up durations were limited in most primary studies, as research was designed to evaluate its use during acute, time-sensitive events. Data for long-term effects are not fully established across its indications, and evidence is limited regarding the durability of acute symptom management over extended timeframes. One key limitation is that study designs differ across trials, with some historical research having modest sample sizes, and comparative evidence for specific groups like pregnant women remains insufficient.

Key Studies & References

  1. Diazepam - StatPearls - NCBI Bookshelf - NIH
  2. Lorazepam v. diazepam for pediatric status epilepticus (Comparative RCT data used for cessation/ventilation rates)
  3. CIWA-Ar for Alcohol Withdrawal (Standardized Clinical Rating Scale and Protocol Context)
  4. Sedative Premedication Guidelines at RCH (Context for Pre-Procedure Relief/Agitation use)

Frequently Asked Questions (FAQ)

Common questions about Diazepam Injection (FAQ)

Q: Does Diazepam Injection work the same way as the oral tablet version?

A: The active ingredient, diazepam, works by the same mechanism (potentiating GABA) regardless of the form. It functions by enhancing the effects of the brain’s natural calming messenger, GABA, to slow down excessive nerve activity. However, the injection is specifically formulated to be fast-acting, typically achieving its effect within one to three minutes when given into a vein, which is why it is used in acute and emergency settings.

Q: Why is a rapid IV injection of Diazepam sometimes associated with local pain?

A: Regulatory documents indicate that rapid administration into a vein can cause local reactions, which may include pain, swelling, and inflammation of the vein (phlebitis) at the injection site. Official guidance indicates that the medicine is administered slowly (at least one minute for every 5 mg) into a large vein to help minimize this possibility.

Q: What is meant by "anterograde amnesia" in the context of Diazepam Injection?

A: The official product information notes that this medicine can cause amnestic effects. This means it may cause a temporary form of memory loss, specifically interfering with your ability to form new memories for events that happen after the injection is administered.

Q: Can the injection cause temporary memory loss or amnesia?

A: Amnesia, or temporary memory loss, is listed in the official safety profile as an uncommon side effect. This is one of the Central Nervous System (CNS) effects noted in regulatory documents.

Q: What are the risks of suddenly stopping Diazepam Injection after receiving multiple doses?

A: The official label notes that continued use, even if only intermittent, may lead to clinically significant physical dependence. Regulatory documents state that abrupt discontinuation or rapid dosage reduction, if dependence is present, may precipitate acute withdrawal reactions.

Q: Does Diazepam Injection affect a person's ability to drive or operate machinery afterward?

A: Due to its powerful Central Nervous System (CNS) depressant effect, the official label advises that patients should be cautioned against engaging in hazardous occupations after receiving the injection. These activities include operating machinery or driving a motor vehicle, as mental alertness may be significantly reduced.

Q: Why is there a warning about using Diazepam Injection in patients with a history of substance abuse?

A: Regulatory documents warn that benzodiazepines carry a risk of abuse, misuse, and addiction. Extreme caution is mandated when administering the injection to individuals with a history of alcohol or drug abuse, as they are considered to have a heightened potential for dependence and misuse.

Q: How long can the injection form of diazepam be used before switching to an oral form?

A: Official administration guidelines indicate that this injection is intended only for short-term, intermittent use for managing acute symptoms, not for continuous, long-term maintenance. Once an acute condition is stabilized, a change in therapy, such as to an oral agent or a non-benzodiazepine agent for long-term control, is generally considered.

Q: How quickly does Diazepam Injection start to work after being administered into a vein?

A: According to authoritative medical sources, when the injection is administered directly into a vein, the onset of action is generally rapid, typically occurring within approximately one to three minutes.

Q: What is the general duration of effect for a single dose of the injection?

A: Diazepam is considered a long-lasting medicine. The sedative duration of action from a single dose can persist for more than 12 hours. However, for certain indications like acute seizures, the initial therapeutic effect may be shorter, requiring monitoring.

Q: Why is the effect of Diazepam Injection sometimes shorter for seizures than for anxiety?

A: Official documents note that the initial effect after intravenous administration for seizure control can be short-lived, leading to a return to seizure activity in a significant proportion of patients. This short duration of the anti-seizure effect is why a return to seizure activity is sometimes noted soon after the initial dose.

Q: Will I feel completely alert immediately after the effects of the injection wear off?

A: It is unlikely to feel completely alert immediately. The parent drug and its active breakdown components (metabolites) have a prolonged half-life and can remain in the body for an extended period. Because of this, the effects of the medicine on the central nervous system may persist, meaning a complete return to baseline alertness may not be immediate.

Q: What are the signs of a "paradoxical reaction" to Diazepam Injection?

A: Paradoxical reactions are listed as rare effects that run counter to the drug's expected sedating effects. Signs include unusual behaviors such as acute excitement, agitation, hallucinations, increased muscle stiffness (spasticity), insomnia, or rage. Official documents state that if these effects occur, the use of the medicine should be discontinued.

Q: Is injection site pain a common side effect of Diazepam Injection?

A: Yes, local reactions at the administration site are specifically listed as common side effects in regulatory documents, occurring in 1% to 10% of users. This includes pain, tenderness, and phlebitis (vein inflammation).

Q: Is there a list of specific prescription medicines that are contraindicated with the injection?

A: Official documents highlight several specific interactions. These include classes of Central Nervous System (CNS) depressants, such as Opioids, due to the additive risk of profound sedation and respiratory problems. Additionally, certain inhibitors of drug metabolism like Cimetidine and enzyme inducers like Rifampicin are noted to interact, altering the concentration of diazepam in the body.

Q: Can herbal supplements interact with the effects of Diazepam Injection?

A: Yes, certain herbal supplements may interfere with the metabolism of diazepam, which can lead to changes in the drug concentration in the body. Authoritative sources note that supplements such as St. John's Wort and Ginkgo are examples of substances that may interact. It is important to disclose all supplements to the prescribing professional.

Q: Are there any known food interactions, like with grapefruit, for the injection?

A: Yes, regulatory and authoritative sources indicate that grapefruit and grapefruit juice are known to interact with the way the body breaks down (metabolizes) diazepam. This interaction can reduce how quickly the drug is eliminated, which may lead to dangerously increased drug concentrations and a higher risk of side effects.

Q: Is Diazepam Injection safe to use during pregnancy for emergency situations?

A: Official documents state that the drug is generally Not Recommended during pregnancy, especially during the first and third trimesters. This is due to noted risks, including the potential for congenital malformations if used early in pregnancy, or sedation and withdrawal symptoms in the newborn if used close to delivery.

Q: What is the current official recommendation regarding breastfeeding after receiving the injection?

A: Diazepam is excreted into breast milk. According to the NIH’s LactMed database, after a single injection dose, there is generally not a need to wait to resume breastfeeding. However, with a newborn or premature infant, a cautious approach may be to wait 6 to 8 hours before resuming nursing, and infant monitoring for signs of sedation or poor feeding is noted, particularly during long-term use.

Q: Is Diazepam Injection suitable for use in all children, including newborn babies?

A: Official labels indicate that the use of Diazepam Injection in neonates (30 days of age and younger) is not established and is therefore not recommended. For older children, administration is guided by weight-based requirements and subject to specific constraints regarding the rate of delivery.

Q: Why is the injection considered for short-term or acute use rather than long-term management?

A: The injection is intended for acute and short-term use because the continued or prolonged exposure to benzodiazepines can lead to the development of clinically significant physical dependence. The risks associated with dependence and the withdrawal symptoms that occur upon discontinuation are the primary reasons it is not used for long-term management.

How should Diazepam Injection be stored and disposed of?

How to Store and Dispose of Diazepam Injection?

Strict storage and disposal requirements for Diazepam Injection are mandated by regulatory agencies due to its status as a controlled substance and its chemical stability needs.

Storage Requirements

Requirement Constraint
Temperature Store at 20 to 25^circC (68 to 77^circF), equivalent to USP Controlled Room Temperature.
Protection Must be protected from light and stored in its original, sealed container.
Security Keep in a locked cabinet or secure area, out of sight and reach of children, to prevent misuse.
Handling Do not mix or dilute the injection with other solutions or drugs in the syringe or infusion container.

Disposal Requirements

Unused or expired medication should be returned to an authorized drug take-back program. Healthcare facilities must destroy unserviceable inventory by methods that render it non-retrievable, conforming to federal and local hazardous waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Diazepam Injection found in:

A-Z Index: